. 2019 Dec 1;26(6):e773–e784. doi: 10.3747/co.26.5517

TABLE III.

Efficacy of monoclonal antibodies against the epidermal growth factor receptor (EGFR) and bevacizumab based on primary tumour location in patients with metastatic colorectal cancer

Reference (trial name)	Treatment arms	Median overall survival (%)								p for interaction

		Left-side disease				Right-side disease

		Anti-EGFR	No anti-EGFR or bevacizumab	HR	95% CI	Anti-EGFR	No anti-EGFR or bevacizumab	HR	95% CI
Boeckx et al., 2017⁶⁵ (PRIME)	FOLFOX with or without panitumumab	30.3 (n=81)	23.6 (n=76)	0.73	0.57 to 0.93	11.1 (n=19)	15.4 (n=24)	0.87	0.55 to 1.37	—

Tejpar et al., 2017⁶⁴ (CRYSTAL)	FOLFIRI with or without cetuximab	28.7 (n=142)	21.7 (n=138)	0.65	0.50 to 0.86	18.5 (n=33)	15.0 (n=51)	1.08	0.65 to 1.81	0.0241⁷

Tejpar et al., 2017⁶⁴ (FIRE)	FOLFIRI plus cetuximab vs. bevacizumab	38.3 (n=157)	28.0 (n=149)	0.63	0.48 to 0.85	18.3 (n=38)	23.0 (n=50)	1.31	0.81 to 2.11	0.0015⁷

Venook et al., 2017⁶⁷ (CALGB/SWOG 80405)	FOLFOX or FOLFIRI plus cetuximab vs. bevacizumab	39.3 (n=173)	32.6 (n=152)	0.77	0.59 to 0.99	13.9 (n=71)	29.2 (n=78)	1.36	0.93 to 1.99	0.005⁷

Qin et al., 2018⁶⁶ (TAILOR)	FOLFOX with or without cetuximab	22.0 (n=146)	18.7 (n=162)	0.69	0.53 to 0.90	11.3 (n=45)	9.3 (n=38)	0.94	0.58 to 1.51	0.0839

Quenet et al., 2018³⁷ (PEAK)	FOLFOX plus panitumumab vs. bevacizumab	43.4 (n=53)	32.0 (n=54)	0.84	0.22 to 3.27	17.5 (n=22)	21.0 (n=14)	0.45	0.08 to 2.49	—

HR = hazard ratio; CI = confidence interval; FOLFOX = fluorouracil–leucovorin–oxaliplatin; FOLFIRI = fluorouracil–leucovorin–irinotecan.